When you donate to Sprint for Life®, your money helps fund clinical and translational research for ovarian cancer.
This also includes grants for new areas of research that improve detection, prevention, treatment, and positively impact survivorship. Each year, one or two $50,000 Sprint for Life research grants are awarded. These grants are a platform for researchers to fulfill larger grants awarded by national groups and government agencies.
Rafet Basar, M.D.
Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer
Nidhi Sahni, Ph.D.
Systems-guided rational design of novel epigenetics-based combination therapy in ovarian cancer
Sanghoon Lee, Ph.D.
Extracellular vesicles (EVs) for assessment of drug response in patients with HGSC
Larissa A. Meyer, M.D.
Mediators of cancer-related fatigue in ovarian cancer survivors
Nicole Fleming, M.D.
Preventing blood clots in patients with ovarian cancer
Wei Hu, M.D., Ph.D.
Improving anti-angiogenesis therapy for ovarian cancer
Arvind Rao, Ph.D.
Predictors of response to therapy in patients with ovarian cancer
Pratip Bhattacharya, Ph.D.
Metabolic Imaging of ovarian cancer
Kelsey Mathieu, Ph.D.
Early detection ovarian cancer through nanomagnetic relaxometry
Yunfei Wen, Ph.D.
Promoting autophagic catabolism in chemoresistant ovarian cancer
Alpa M. Nick, M.D.
Circulating tumor cells in ovarian cancer
Yuexin Liu, Ph.D.
Predicting therapy response in ovarian cancer
Wei Zhang, Ph.D.
MicroRNA therapy in ovarian cancer
Lois Ramondetta, M.D.
Targeting stress factors in ovarian cancer
Kathleen Schmeler, MD
Inherited and sporadic BRCA alterations in ovarian cancer
Vahid Afshar-Kharghan, M.D.
The role of complement pathway in ovarian cancer
Kwong K. Wong, Ph.D.
Understanding the molecular changes in cells that cause a rare ovarian cancer type: low grade serous carcinoma
Bulent Ozpolat, M.D., Ph.D.
Tumor-targeting siRNA – nanovectors for novel molecular therapy of metastatic ovarian cancer
Bryan Hennessy, M.D.
Proteomics to find markers of chemotherapy resistance in ovarian cancer
Michael Frumovitz, M.D., M.P.H.
The study of quality of life in women receiving second-line chemotherapy for recurrent ovarian cancer
Robert Luo, M.D., Ph.D.
Evaluating tumor suppressor genes and apoptosis-independent autophagic cell death in ovarian cancer cells
Lois Ramondetta, M.D.
Evaluating the role of spirituality in coping with and surviving ovarian cancer
Judith Ann Smith, Pharm.D., FCCP, BCOP
Evaluating the possible ways to reverse drug resistance during treatment of ovarian cancer
Anil Sood, M.D.
How the neuroendocrine system regulates growth factors in ovarian cancer patients
Charlotte Sun, Dr.P.H., M.P.H.
Evaluating quality of life of patients receiving high dose chemotherapy for ovarian cancer
Diane Bodurka, M.D.
Evaluating the preferences of toxicities for ovarian cancer patients on chemotherapy
Rosemarie Schmandt, Ph.D.
The study of genetic alterations in a specific class of molecules known as kinases, that are frequently observed in the development of ovarian cancer tumors